Evaluation of the Oncoral® Test in Epidermoid Carcinomas of the Upper Aerodigestive Tract
NCT01361100 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 485
Last updated 2012-10-02
Summary
This is a multicentric feasibility study aimed to evaluate the Oncoral® test. The study includes 2 steps. The first one aims to validate the algorithm defined at the time when the test was developed in patients with different tumour stages. Patients will be enrolled before any treatment. They will immediately undergo the test. No follow-up will be realized. In total, 100 patients will be included in this first step. The estimated period of inclusion is 6 months.
If the algorithm is validated, the second step of the study will start. The purpose is to determine the characteristics of the test. Enrollment will concern smokers and alcohol drinkers at high risk of developing an epidermoid carcinoma of the upper aerodigestive tract. Patient follow-up will vary with both the result of the test and the biopsy, up to a maximum of one year. In total, 385 patients will be enrolled in this step during an estimated period of 18 months.
Conditions
- Carcinoma
Interventions
- DEVICE
-
Oncoral® test
The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.
Sponsors & Collaborators
-
Clinident Institute
collaborator UNKNOWN -
Centre Leon Berard
lead OTHER
Principal Investigators
-
Philippe ZROUNBA, MD · Centre Leon Berard
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-12-31
- Primary Completion
- 2015-06-30
- Completion
- 2015-06-30
Countries
- France
Study Locations
More Related Trials
-
Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer Cachexia
NCT05954117 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
NCT00573131 ·Status: TERMINATED ·Phase: PHASE2
-
Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
NCT03437200 ·Status: TERMINATED ·Phase: PHASE2
-
Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy
NCT02551458 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
INEC Study: Immuno-modulating Enteral Nutrition in Cancer
NCT00333099 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer
NCT00760604 ·Status: TERMINATED ·Phase: PHASE3
-
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
NCT00544362 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Complete Clinical Responders to Definite Chemoradiation in Esophageal Cancer : a Survival Analysis
NCT01525953 ·Status: COMPLETED
-
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
NCT02569242 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma
NCT02998268 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer
NCT00911092 ·Status: COMPLETED ·Phase: PHASE4
-
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT06888531 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer
NCT06523374 ·Status: RECRUITING ·Phase: NA
-
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
NCT01196390 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
NCT00561197 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer
NCT03529669 ·Status: COMPLETED ·Phase: NA
-
PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer
NCT00669292 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer
NCT00578201 ·Status: COMPLETED ·Phase: PHASE2
-
Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer
NCT00628368 ·Status: COMPLETED ·Phase: NA
-
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer
NCT00632333 ·Status: UNKNOWN ·Phase: PHASE1
-
Audit of the Spanish EURECCA Esophagogastric Cancer Registry
NCT03541629 ·Status: COMPLETED
-
Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only
NCT00653107 ·Status: TERMINATED ·Phase: PHASE3
-
Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus
NCT01348217 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma
NCT00215462 ·Status: COMPLETED ·Phase: PHASE2
-
Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma
NCT01586182 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2